Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Midazolam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Crossject
Deal Size : Undisclosed
Deal Type : Agreement
Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®
Details : Under the agreement, Syneos Health will provide support in all pre-launch and launch activities for Zepizure (midazolam), an epileptic rescue therapy for epileptic seizures.
Product Name : Zepizure
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 01, 2024
Lead Product(s) : Midazolam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Crossject
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Odyssey Health
Deal Size : Undisclosed
Deal Type : Agreement
Details : ONP-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of moderate traumatic brain injury. It crosses BBB & activates gene response leading to the production of proteins that reduce inflammation, oxidative str...
Product Name : PRV-002
Product Type : Steroid
Upfront Cash : Undisclosed
November 16, 2023
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Odyssey Health
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : CELZ-201
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Creative Medical Technology
Deal Size : Undisclosed
Deal Type : Partnership
Details : CELZ-201 is the First Novel Allogenic Cellular Therapy in the Dorsal Artery of the Pancreas. CELZ-201 leverages unique approach harnessing the power of PRDC to multi-potentialities, including self-renewal ability, low antigenicity, reduced toxicity, with...
Product Name : CELZ-201
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 03, 2023
Lead Product(s) : CELZ-201
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Creative Medical Technology
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Daridorexant HCl
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Idorsia Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Details : Idorsia to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant would be the first dual orexin receptor antagonist made available to patients with insomnia.
Product Name : Quviviq
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 26, 2022
Lead Product(s) : Daridorexant HCl
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Idorsia Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Study Phase : Phase III
Sponsor : Idorsia Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The strategic collaboration brings Idorsia’s lead investigational compound, daridorexant, and expertise in the science of the orexin system, together with Syneos Health’s robust customer-facing sales expertise and proven track record in launching new...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
August 31, 2020
Lead Product(s) : Daridorexant
Therapeutic Area : Sleep
Highest Development Status : Phase III
Sponsor : Idorsia Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Syneos Health will provide both strategic and operational solutions for three lead Daiichi Sankyo DXd antibody drug conjugates (ADC): DS-1062, U3-1402 and DS-8201 (known as ENHERTU®).
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
May 28, 2020